Topline Results: Phase 3 Energize Study of Pyrukynd in Thalassemia
3
Forward-looking statements
This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those regarding: the potential benefits of mitapivat; Agios' plans for the future clinical development
of mitapivat in alpha-and-beta thalassemia; and Agios' strategic plans and prospects. The words "anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product
candidate Agios or its collaborators is developing will successfully commence or complete necessary preclinical and clinical development phases, or that
development of any of Agios' product candidates will successfully continue. Moreover, there can be no guarantee that any medicines ultimately commercialized by
Agios will receive commercial acceptance. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation.
Management's expectations and, therefore, any forward-looking statements in this presentation and various remarks we make during this presentation could also be
affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of
pandemics or other public health emergencies to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research
activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future
approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including
subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA
or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite
regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; Agios' ability to obtain, maintain and
enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to establish and maintain key collaborations;
uncertainty regarding any milestone or royalty payments related to the sale of Agios' oncology business or its in-licensing of TMPRSS6 siRNA, and the uncertainty
of the timing of any such payments; uncertainty of the results and effectiveness of the use of proceeds from the transaction with Servier; competitive factors; and
general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings
with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation and various remarks we make during this
presentation speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.View entire presentation